1. FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL. (June 2017) Authors: Gressin, R.; Daguindau, N.; Tempescul, A.; Moreau, A.; Carras, S.; Cartron, G.; Schmitt, A.; Houot, R.; Dartigeas, C.; Pignon, J.; Corm, S.; Bannos, A.; Mounier, C.; Dupuis, J.; Macro, M.; Fleury, J.; Jardin, F.; Karlin, L.; Damaj, G.; Feugier, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗